TTrialPathMatch Me to Trials
← Back to trials
RecruitingBladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Eligible age

18+ yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Sponsor: Guardant Health, Inc.

You may qualify if…

  • ✓ Age \> 18 years old AND
  • ✓ Initial treatment is given with curative/radical intent AND
  • ✓ Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND
  • ✓ Provided written informed consent to participate in the study AND
  • ✓ Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND
  • ✓ Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 3 years as outlined in the study protocol and informed consent AND
  • ✓ Have at least one Landmark blood sample collected. Landmark samples are collected 3-12 weeks after surgery, chemotherapy and/or radiation/chemoradiation as applicable based on the participant's planned treatment regimen
  • ✓ Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:

You may not qualify if…

  • ✕ History of allogeneic organ or tissue transplant
  • ✕ Index cancer has predominantly neuroendocrine histology
  • ✕ History of another primary cancer diagnosed within 3 years of enrollment, with the exception that in situ cancers, non-melanoma skin carcinomas, localized low- or intermediate risk prostate cancers (defined as cancers confined to the prostate with Gleason score of 7 or lower and prostate-specific antigen (PSA) of less than 20), and stage I papillary thyroid carcinoma, and participants with bilateral/multifocal tumors within the same organ (for example, bilateral breast cancer) are allowed if diagnosed within 3 years of enrollment
  • ✕ Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC)

Where it's recruiting

Alabama

Birmingham

Arizona

Chandler

Arkansas

Hot Springs

California

La Jolla · Newport Beach · Redwood City · Sacramento

Colorado

Aurora

Florida

Hollywood · Lakeland

Louisiana

New Orleans · Shreveport

Maine

Lewiston

Michigan

Grand Rapids

Minnesota

Rochester

New Jersey

East Brunswick

Source: ClinicalTrials.gov · NCT05059444 · last updated 2026-09-14

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation · TrialPath